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Some common diseases are known to have an inherited component, however, their
population- and familial-incidence patterns do not conform to any known monogenic
Mendelian pattern of inheritance and instead they are currently much better explained if
an underlying polygenic architecture is posited. Studies that have attempted to identify
the causative genetic factors have been designed on this polygenic framework, but so
far the yield has been largely unsatisfactory. Based on accumulating recent observations
concerning the roles of somatic mosaicism in disease, in this article a second framework
which posits a single gene-two hit model which can be modulated by a mutator/anti-
mutator genetic background is suggested. I discuss whether such a model can be
considered a viable alternative based on current knowledge, its advantages over
the current polygenic framework, and describe practical routes via which the new
framework can be investigated.
Keywords: somatic mosaicism, mutator alleles, anti-mutator alleles, nanopore sequencing, rare variants, RVAS,
genome wide association studies, rare variant association studies
INTRODUCTION
Some diseases within the human population are described as being ‘complex’ or ‘multifactorial’
in that they have an underlying inherited genetic etiology which contributes to disease risk along
with environmental factors. These occur relatively common within the population and examples
include congenital disorders such as cleft lip and palate, pyloric stenosis, clubfoot, and neural tube
defects; those that can manifest at some point in childhood/early adulthood such as autism and
schizophrenia; and those that can appear later in life such as Alzheimer’s disease. The proportion
of genetic and environmental contributions to these types of diseases varies, but the proportion of
variance of each of these particular diseases observed within a population which is due to variance
in genetic factors is sometimes referred to as the ‘heritability’ and can be calculated via multiple
methods. The simplest method, to obtain an estimate, is by observing the diﬀerence in concordance
for the disease between monozygotic and dizygotic twins. The aforementioned diseases as well as
several others are estimated to have a high heritability. The current consensus is that this genetic
contribution is polygenic, such that multiple genetic loci interact in some fashion in order for the
disease to manifest and such a model was put forth primarily based on the observed patterns of
population- and familial-incidences of such diseases. In the last decade or so, various population-
based large scale eﬀorts to unmask the precise genetic factors responsible for disease manifestation
have been based on this model, and have included investigations probing genetic variations that
occur commonly, and more recently those that occur more rarely within the population. Overall,
the output from such investigations have been disappointing in terms of providing little in the
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way of identifying and characterizing causal variants that actually
play a signiﬁcant role in disease manifestation. Here, I propose
and describe an alternative theoretical model and consider
whether the new model would be consistent with the population
andmanifestation characteristics of the diseases as well as current
knowledge in genetics. I also discuss the merits and potential
ﬂaws of such a framework in comparison to current models,
and deﬁne routes by which the framework could be tested and
utilized.
POLYGENIC THEORY,
DISEASE-THRESHOLD, AND
THE CARTER EFFECT
Fisher (1918), arguably one of the most important thinkers in
the history of the biological sciences, published a work which
he entitled ‘The correlation between relatives on the supposition
of Mendelian inheritance’. It was a landmark moment in our
understanding of the genetics of inheritance. With the use
of several mathematical applications, which many geneticists
would struggle to grasp the inner-workings of, he settled an
ongoing and at times heated debate between two major schools
of thought regarding fundamental aspects of inheritance. On
one side were the ‘Mendelians’ who championed the ideas of
Mendel that single entities, now known as genes, were suﬃcient
to determine phenotypic traits; and on the other side the
statistically inclined ‘biometricians’ who argued that the majority
of phenotypic traits displayed a continuous variation within the
population and therefore at odds with this Mendelian idea of
inheritance which rather predicted a dichotomous appearance of
characters. Fisher’s (1918) mathematical intuition and training
enabled him to introduce novel statistical models to demonstrate
that ‘cumulative Mendelian factors seem to ﬁt the facts very
accurately’ as he put it; meaning that several genetic factors
contribute in an additive manner to determine the value of an
observed continuous trait. This came to be known as ‘polygenic
theory’ and the work further laid the foundations of ‘quantitative
genetics’ which concerns the study of genotype–phenotype
correlations within populations.
The statistical models, Fisher (1918) introduced in his seminal
paper and in further works (Fisher, 1922) are still widely
used today in various ﬁelds of science. Though Fisher (1918)
developed polygenic theory with the particular intention to
explain continuous traits within populations, shortly following
his death, his theory was extended in an attempt to explain
the presence of dichotomous characters (Falconer, 1965), i.e.,
those characters previously acknowledged to be consistent with
a Mendelian single-gene model. There was good motivation
behind making such an extension: it was observed that many
common diseases of a dichotomous nature that displayed some
degree of familial clustering, displayed a rather low recurrence
incidence amongst relatives and thus did not conform to any
known pattern of Mendelian inheritance. Already inherent to
Fisher’s (1918) polygenic model was that an individual is much
less likely to develop the disease if he/she needs to inherit
several alleles in order for the disease to manifest compared to
if he/she needed to inherit just one or two (as in Mendelian
inheritance), thus potentially explaining the reduced familial
recurrence risks. However, to reconcile the observations of the
dichotomous nature of diseases with Fisher’s (1918) model, the
idea of ‘threshold’ was included where it is postulated that
many genes do in fact contribute to disease manifestation in
an additive fashion, but that only when a particular threshold
biological value is breached, does the disease manifest. Thus the
‘polygenic threshold model’ as it became known neatly ticked all
the required boxes, and in one form or another, has remained
a mainstay as an explanation for inherited diseases which do
not conform to any classic Mendelian pattern whilst displaying
a dichotomous manifestation.
Indeed, this very concept of disease-threshold was
incorporated into an explanation for another more speciﬁc
observation regarding the population characteristics of some of
these diseases: that a few displayed sex dimorphism where one
particular sex is more commonly aﬀected than the other (Carter
and Evans, 1969). For example, in some disorders males are more
commonly aﬀected, and it is proposed that females must possess
a higher threshold for disease expression: therefore a higher
number of disease susceptibility alleles need to be inherited for
the disorder to manifest in females. As a consequence, this would
also mean that when females are aﬀected, it would suggest a
higher ‘genetic load’ of disease susceptibility alleles within the
family and thus a higher recurrence risk for her relatives. Thus
in a sex dimorphic polygenic disease, when the usually less
commonly aﬀected sex presents with the disease within a family,
there is predicted to be a higher recurrence risk for relatives. This
phenomenon became known as the ‘Carter eﬀect’.
It may be of some note at this point that Fisher (1918)
appeared quite happy to let the Mendelians ‘have’ the
dichotomous traits, as is quite apparent from the fact that he
made little eﬀort to explain them using his polygenic theory,
though he had plenty of scope, and no doubt, the intellectual
vision to do so. Further, it is imperative to point out here
that though the later proposed disease-threshold model can
sometimes be useful in helping to estimate the recurrence risk
of a disease once the population- and familial-incidences are
known, as well as in making heritability predictions, there is
currently no direct evidence to support the model. Indeed, it
should at least be of a slight concern that the Carter eﬀect is
widely cited as evidence for the threshold model, as conversely
there is no evidence to support the basis of the Carter eﬀect, nor
even a proposed biological mechanism via which one particular
sex would have a higher/lower threshold for the expression of
diseases.
FROM COMMON VARIANTS TO RARE
VARIANTS
Rarer inherited diseases tend to display a monogenic Mendelian
pattern of inheritance within families, and toward the end
of the last century, linkage and mapping studies had been
very successful in identifying the genetic causes of many of
these. However, similar types of studies proved insuﬃcient
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for identifying the causes of more common inherited diseases
suspected to have an underlying polygenic determination.
Indeed this diﬃculty was attributed to the existence of several
causative genes, each only contributing a small-eﬀect on disease
manifestation, making them diﬃcult to pinpoint using standard
genetics approaches. Human genome sequencing projects earlier
on this century, however, revealed that some genetic variations
occurred fairly commonly within the population, usually as
single nucleotide polymorphisms (SNPs). It was hypothesized
that these common genetic variants were likely to be responsible
for polygenic disease manifestation, i.e., phenotypic variance
would be dependent on the contribution of several genetic
variants each of which would make only a small contribution
toward the manifestation of the disease; and thus these genetic
variants needed to occur fairly commonly within the population
to account for the prevalence of the disorders. This became
known as the ‘common disease-common variant’ hypothesis, and
it seemed somewhat ﬁtting that technological advances being
made at the time meant that this could be tested using physical
molecular genetics experiments in approaches termed genome
wide association studies (GWAS). The highs and lows of GWAS
studies have been discussed and debated extensively elsewhere
and such a discussion is not necessary here. But to cut a long
story short, the current consensus is that these common genetic
variants at most account for very little of the causative genetic
contribution to these diseases.
Focus in the ﬁeld has more recently turned its attention
toward rare genetic variants to search for this otherwise ‘missing
heritability’ (Manolio et al., 2009). In this case it is hypothesized
that low frequency genetic variants may have larger-eﬀect sizes,
thus with fewer alleles needing to contribute in a polygenic
manner toward disease manifestation. Investigations to identify
these causative rare genetic variants in patients can now be
performed with next-generation-sequencing technologies and
are sometimes referred to as Rare-Variant-Association-Studies
(RVAS). Investigations have shown that rare genetic variants are
highly abundant in human populations and indeed that these
variants are more likely to have larger deleterious biological
eﬀects (Nelson et al., 2012; Tennessen et al., 2012) as predicted
by the ‘rare-variant-common disease’ hypothesis. Indeed, it has
been suggested that an extensive ‘polygenic burden’ of rare
variants within individuals might contribute to the prevalence
of the diseases within human populations (Purcell et al., 2014).
Currently, the main consensus is that the case/control population
cohort sizes would need to be substantially large for the actual
causative variants to be identiﬁed, thus making eﬀorts to identify
disease-causing genes very challenging (Derkach et al., 2014;
Lee et al., 2014; Robinson et al., 2014; Sham and Purcell, 2014;
Zhang, 2015). There are additional concerns over the reliability
of in silico methods that are being used to predict whether rare-
variants are likely to be deleterious (Henn et al., 2015). Further,
the RVAS studies that have been performed so far indicate that
most rare variants in fact only have modest-to-small eﬀect sizes
on phenotypic variation (Auer and Lettre, 2015). However, it is
still relatively early days for such RVAS studies, and as GWAS
studies did until a few years ago, they currently dominate the
complex genetic diseases research landscape.
BOX 1 | Fundamental components of the new model.
(1) A generally high, but varying, degree of locus heterogeneity exists for
these diseases.
(2) Biallelic inactivation of a single gene is both necessary and sufficient for
disease manifestation.
(3) The first mutation is inherited from a carrier parent. A random second
hit occurs somatically; most likely at some rapid growth phase during
embryonic/fetal development, but may also occur during childhood.
(4) Genetic variants which are inherited from both parents alter the frequency
of an individual’s mutation rate, and these are a component of the genetic
background. Several such mutator/anti-mutator alleles contribute in an
additive fashion to modulate the probability of the second hit occurring.
(5) When sex dimorphism is observed, it can be explained by X-linked
inheritance within some families, though with deviations from the
expected classic Mendelian pattern, rather than the Carter effect.
(6) The framework is more likely to apply to diseases with a dichotomous
manifestation and to diseases with a suspected developmental
component, but may not be limited to diseases of this character.
(7) Environmental factors might contribute to disease risk, but in a lot
of cases, they play a much lesser role than predicted by the current
multifactorial model.
AN ALTERNATIVE THEORETICAL
FRAMEWORK
When quizzed by an astute undergraduate student, ‘why such a
big fuss about rare variants now?’ it is somewhat embarrassing to
have no much better answer than ‘because we were mostly wrong
about common variants’. We could attempt to lessen the blow by
explaining that we are technologically in a much better position
today to investigate rare variants in the laboratory, but in truth
the student has a point: since both hypotheses were proposed,
little has changed regarding our overall understanding of these
variants and nothing has changed regarding the theoretical
frameworks upon which both of the hypotheses were synthesized.
Thus without the hindsight that the common variant hypothesis
is deﬁcient, there is little that we have learnt to suggest that the
polygenic rare variant hypothesis is any more scientiﬁcally sound
(Gibson, 2012; Robinson et al., 2014; Auer and Lettre, 2015;
Henn et al., 2015). This makes it very acceptable, even prudent,
to seriously consider alternative theoretical frameworks, even
though they may be against major consensus held for decades.
Here, I attempt to piece together a consistent framework which is
based on empirical and experimental observations of colleagues
in the ﬁeld, past and present. The fundamental aspects of the
conceptual framework are outlined in Box 1; and the rationale,
merits, and potential shortcomings, are discussed in the sections
below.
CONSIDERING THE GENERAL
PATTERNS OF OBSERVED FAMILIAL-
AND POPULATION-INCIDENCES
A Single-Gene Two-Hit Model
Much of the inspiration for writing this article came from
considering observations and ideas of a study entitled ‘Genetics,
Chance, and Morphogenesis’ by Kurnit et al. (1987) published
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almost 30 years ago. The study investigated the roles of natural
random probabilistic events that occur during early development,
such as endocardial cell migration, and their inﬂuence over
biological process by performing computer simulations. They
observed a high degree of probabilistic variability in the outcomes
of their simulations, which was distributed continuously: and in
fact, the output appeared to resemble the normal distribution
curves predicted by polygenic theory. They further demonstrated
that this also held true if they included a single gene into their
probabilistic model, and propose that multifactorial diseases may
thus in fact be caused by inheritance of one or two copies of a
single defective gene but also by chance events that occur during
normal embryonic development as an important contributing
factor. A limitation acknowledged by Kurnit et al. (1987) and
extended on later by colleagues (Hook, 1988), was that the model
didn’t satisfactorily account for steep falling-oﬀ of recurrence
risk with diminishing relatedness as well as it should (addressed
in ‘Mutator/Anti-mutator Genetic Background section’ below).
Further, whereas the occurrence of sporadic birth defects may
be attributed to some random very bad luck event during
development, whether such events occur frequently enough
to interact with genetic factors to signiﬁcantly contribute to
relatively common diseases within the population is perhaps
much less likely. Here, I suggest a variation to the model such
that only one defective copy of a single gene is inherited; and
that rather than an adverse random biological processes during
development, the chance element comes from inactivation of
the second copy of the gene via random mutation during early
development or growth. This two-hit model would explain the
reduced recurrence-risk within aﬀected families compared to
classic Mendelian disorders.
Such a two-hit model is of course at the foundation of our
understanding of how mutations in tumor suppressor genes
contribute to some forms of cancer (Knudson, 1971). Cancerous
cells and tissue represent special examples where accumulating
mutations in cell cycle regulators and DNA repair factors
accelerate the rates of mutation such that likelihood of the
second-hit is increased, and where a new mutations can confer
a growth advantage to the cell, thus expanding the target for the
next cancer-promoting mutation to occur. The primary reason
why such a model is not normally extended to non-cancerous
disease is that such events of successive growth-promoting
mutations are unlikely in healthy tissue. However, the model
presented here posits that only a single mutation needs to occur
for disease manifestation, and that this most likely occurs during
a rapid growth phase such as in embryonic or fetal development,
where a rapid rate of cell division is already naturally inherent
to most cells. It is also important to note here that most gene
disruptions will not signiﬁcantly alter growth rates, whether it’s
a reduction or an increase, or trigger apoptosis, as is sometimes
erroneously assumed. Depending on how early these mutations
occur in development they can either eﬀect an entire organ or
physiological system, or speciﬁc circuits within an organ – but
enough tomanifest as disease. Highly complex organs, such as the
brain, probably require a smaller amount of tissue to be aﬀected
for the disease to manifest. Such considerations would also
explain why these diseases would not display a classic Mendelian
pattern, i.e., when both parents are carriers: if both mutations
are inherited this would result in all cells in the oﬀspring being
aﬀected, immediately from the single-cell zygote stage, and thus a
diﬀerent observed phenotype. A rather striking example of this
comes from our knowledge of mutations in the BRCA2 gene:
when one mutation is inherited, there is a predisposition to breast
cancer; whereas when two mutations are inherited it causes a
congenital syndrome, Fanconi’s anemia, where patients instead
display high incidences of leukemia, bone marrow failure, and
other wide and varying phenotypes (Howlett et al., 2002).
What is a crucial consideration, however, is the natural
mutation rate within healthy tissues. This is still an area
of active enquiry and estimates vary (Callaway, 2015). But
what is clear is that estimates of the somatic mutation rate
are consistently considerably much higher than that in the
germline (Garcia et al., 2007; Lynch et al., 2008; Lynch, 2010a,b).
The appearance of mutations within our genomes include
errors incorporated during replication as well those inﬂicted
by mutagens, but an additional very important source is the
commonly occurring spontaneous deamination of methylated
cytosines of CG dinucleotides to thymine. CG dinucleotides
have generally reduced in frequency in genomes over history
due to these spontaneous deamination events, but they remain
more frequently in exons of protein coding genes where their
presence to encode the correct sequence of amino acids is more
crucial. Consequently, when deaminations at these sites do occur,
they are very often identiﬁed as hotspots of causative point
mutations in Mendelian and sporadic genetic disease. No truly
reliable estimate of somatic mutation rate, however, exists, and
this is largely due to our inability over the years to perform
a wide survey to reliably determine the spectrum of sequence
changes within the genomes of multiple tissue regions, although
it is noteworthy that important initiatory studies in this regard
using modern sequencing and computational approaches ﬁnd
very extensive somatic genetic variation when diverse tissues
are sampled (Frank, 2010; O’Huallachain et al., 2012; Behjati
et al., 2014); and more common roles for somatic mosaicism
in disease manifestation has been suggested (De, 2011; Cohen
et al., 2015). Indeed, our observations of non-cancerous human
diseases caused by somatic mutations has been steadily increasing
in recent years as our ability to detect them improves; and
this includes mutations that may accumulate during the lifetime
of an individual in age-related illnesses (Forsberg et al., 2012,
2013; Bonnefond et al., 2013; Aghili et al., 2014), and also new
mutations that occur in early development that may contribute
to the formation of sporadic forms of non-cancerous disease
(Lindhurst et al., 2011; Poduri et al., 2012, 2013; Li et al., 2013;
Dal et al., 2014).
A Mutator/Anti-mutator Genetic
Background
Mutation rates vary between species and they can also be
inﬂuenced by variant alleles of genes encoding DNA replication
and repair machinery within populations (Fijalkowska and
Schaaper, 1995; Wibley et al., 2003; Baer, 2007; Senejani et al.,
2012). Further, the observation that germline and somatic
Frontiers in Genetics | www.frontiersin.org 4 November 2015 | Volume 6 | Article 327
Hussain New model for complex diseases
mutation incidences are often widely diﬀerent within eukaryotic
organisms indicates the existence of factors, likely genetically
encoded, that can exert control over the rate of mutation (Lynch,
2010b). In addition, there are likely several yet other diverse
genetically encoded factors that can inﬂuence mutation rate by
regulating the rates/eﬃciency of mutagen clearance within cells.
Importantly, other classes of genetically encoded factors that
can inﬂuence the mutation rate have also been described; and
these are currently known to range from microRNAs, to factors
which regulate dNTP pools, amongst others (Valeri et al., 2010a,b;
Tili et al., 2011; Ahluwalia and Schaaper, 2013; Alderton, 2013;
Scanlon and Glazer, 2015; Sohl et al., 2015). Thus we likely have
an architecture where genetic variants of a very broad range of
cellular factors capable of signiﬁcantly inﬂuencing the mutation
rate exist, thus potentially resulting in signiﬁcant variance of the
mutation rate amongst individuals within a population.
With regards to the two-hit model presented in the current
framework, once the ﬁrst mutation has been inherited, since the
chance second hit is both necessary and suﬃcient for disease
manifestation, any factors that inﬂuence the probability of the
second hit occurring, will play a signiﬁcant role in determining
disease manifestation. We know that classic Mendelian disease
can sometimes be inﬂuenced by the genetic background which
can modulate the penetrance. Here, it is proposed that the
genetic background also otherwise contains an additional very
important component that contributes to disease manifestation
in this particular framework: a number of mutator and anti-
mutator alleles; and that these variants can be inherited from
both the carrier-parent and the non-carrier parent. Such a
proposal would help explain the steeper falling-oﬀ of recurrence
risk with decreasing relatedness observed for these diseases
compared to the proportionate falling-oﬀ observed in classic
Mendelian disorders. This is perhaps the most important aspect
of this entire framework, and may be indirectly supported
by observations. Mutation rates are known to be elevated in
multicellular species relative to unicellular organisms, and in a
fascinating theoretical undertaking, Lynch (2008) hypothesizes
that multicellularity increases the probability of ﬁtness reduction
associated with somatic damage, but paradoxically in addition
actually encourages the accumulation of mutator alleles that
cause such damage, thereby magnifying the vulnerability to
somatic mutations and disease. He also notes that when
mutator alleles rise to moderate frequencies, considerable
heterogeneity in the mutation rate is expected among individuals.
The general idea of genetic variants commonly inﬂuencing
mutation rates across a population is supported by a large-
scale sequencing study which revealed that mutation rates vary
substantially between families, and the authors thus suggest
that mutation rates may be inﬂuenced by an individual’s
genetic background (Conrad et al., 2011). The notion that
genetic variants in the genetic background which are capable
of signiﬁcantly inﬂuencing the penetrance of disease was
also previously suggested (Demogines et al., 2008). Indeed,
investigations have shown that patients with schizophrenia
caused by newmutations, displayed generally increased mutation
rates compared to control individuals (Girard et al., 2011; Xu
et al., 2012).
Locus Heterogeneity
The pleotropic eﬀect refers to the situation where a single locus
aﬀects more than one phenotypic trait, and plays established
roles in the manifestation of genetic disease (Stearns, 2010).
In contrast, locus heterogeneity describes the situation where a
particular phenotypic trait or disorder can result from mutations
at any one of several distinct loci; this particular concept
likely plays key roles within the proposed framework, as it
could potentially help explain the more frequent occurrence
of complex genetic diseases within the population. A proposal
of locus heterogeneity would also have equally important
implications for other observations regarding the manifestation
characteristics of some of these diseases. For example, it is
sometimes observed that some families aﬀected by a particular
multifactorial disease have a higher incidence risk than others,
most often amongst siblings. In fact if a couple have two
children with a particular disease, the recurrence risk for the
next child steeply increases. Within these families, it is possible
that the particular causative gene is an example of a mutation
hotspot locus thus signiﬁcantly increasing the risk to oﬀspring.
Additionally, the parents could harbor a high number of
mutator alleles/low number of anti-mutator alleles, thus further
increasing the risk. Another observation in a few examples
of multifactorial disease, such as cleft palate and cleft lip and
neural tube defects, is that if a child is severely aﬀected with the
disease, then the recurrence-risk for next child also increases.
This is a little more diﬃcult to fully explain with the current
framework, however, the proposed locus heterogeneity likely
also plays a key role: some genes will encode factors which
when disrupted cause diﬀerent aspects of a biological process
or physiological system to fail, thus though they manifest as
the same observable disease, they do so with varying degrees of
severity.
CONSIDERING CHARACTERISTICS OF
DISEASE MANIFESTATION AND SEX
DIMORPHISM
Many multifactorial diseases display a dichotomous
manifestation. This is most apparent in the congenital diseases
such as cleft palate and cleft lip, pyloric stenosis, clubfoot,
and neural tube defects, but also in others such as autism,
schizophrenia, and bipolar disorder. These and others are much
better explained by the current single-gene model than by the
polygenic model, as the former does not require invoking the
idea of disease-thresholds, the actual biological mechanisms for
which are ill-deﬁned.
As described earlier, the Carter eﬀect is posited as an
explanation for observations of sex dimorphism in the polygenic
threshold model, for which no actual proposed biological
mechanism exists. Within the current framework I suggest that
the examples of sex dimorphic multifactorial diseases might
instead be explained by X-linked inheritance, which only occurs
in some families due to the high degree of locus heterogeneity.
For diseases which display a rather high level of sex dimorphism
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such as in pyloric stenosis, clubfoot, and autism, more of the
causative genes or even just one or two which are mutation
hotspots could be located on the X chromosome; whereas those
that display a more modest degree of dimorphism contain
fewer, perhaps even just one causative X-chromosome gene.
When X-linked inheritance does occur within families, somatic
mosaicism complicates the pattern of X-linked inheritance
expected from the classic Mendelian prediction much more
frequently than it normally would do. For example, since random
X-inactivation occurs at the ∼20 cell stage of the developing
female embryo, and since somatic mosaicism is inherent in
determining disease occurrence under this framework (i.e., only
a smaller amount of tissue needs to be aﬀected), then it is
much more likely that random X-inactivation could lead to
manifestation of the disease, as inactivation of the normal
X-chromosome would only need to occur in a muchmore limited
amount of tissue. Thus in such situations, daughters of mother-
carriers would be more frequently aﬀected than expected, thus
masking the pattern of X-linked inheritance that we expect from
the usual Mendelian prediction where males are mainly aﬀected
after inheriting the faulty gene from a carrier mother.
Indeed, the most common cases of sex dimorphism in
multifactorial disease are where the number of aﬀected males
signiﬁcantly outnumber the number of aﬀected females within
the population. In such cases, if the Carter eﬀect does occur, the
most readily detectable observation would be that relatives of
aﬀected females should be at higher risk than relatives of aﬀected
males. A Danish study which included a cohort of ∼two million
children, ∼3,400 of which had surgery for pyloric stenosis,
found no such correlation (Krogh et al., 2010). In a second
further large-scale study, it was reported that the recurrence
rates of autism spectrum disorders (ASDs) were the same in
families with aﬀected female individuals as with aﬀected male
individuals (Ozonoﬀ et al., 2011). Indeed, the authors of both
of these large-scale studies commented that the observed data
do not support the polygenic threshold model. An interesting
observation, however, was that maternal half-siblings are at a
signiﬁcantly increased risk compared to paternal half-siblings in
a large Danish study reporting on ASD incidence (Grønborg
et al., 2013). The authors propose, that factors associated with
pregnancy and the maternal intrauterine environment contribute
to the risk of developing ASDs; but, the observations may instead
be explained if females are more often carriers of a faulty gene(s),
i.e., one that is X-linked. As is apparent, only a very limited
amount of information can be gleaned from such studies, and the
complications to predicted patterns of inheritance added by the
current framework exacerbates these limitations.
OTHER IMPORTANT CONSIDERATIONS
Genetic Interactions
In Fisher’s (1918) framework, genetic factors contribute to a
continuous trait, such as height, in an additive fashion. It’s a
revered theory amongst geneticists and describes continuous
traits, in an elegant, easy to envisage manner. However, when
used in this fashion in attempts to account for common diseases
within populations, shortcomings become apparent (Nelson
et al., 2013); andmultiplicative models have been suggested where
gene–gene interactions likely play a signiﬁcant role (Risch, 1990;
Wray and Goddard, 2010). Higher order genetic interactions
(HGIs) probably do exist in nature (Taylor and Ehrenreich,
2015), though the roles for these in disease manifestation have
not previously been described, and we have knowledge of only
very few examples of them in biological systems. It has been
suggested that genetic studies fail to detect HGIs, because of a
lack of statistical power (Cordell, 2009; Taylor and Ehrenreich,
2015), but even so, it may indeed be that the roles in disease
manifestation are actually rare. This is since when considering
multiplicative genetic interactions from a biological perspective,
we are referring to speciﬁc genetically encoded allelic products,
rather than any form of the genetically encoded product, that
are able to inﬂuence each other in a biologically meaningful
way. Although attractive as a concept in genetics, from a
cell biology point of view, this is very diﬃcult to imagine as
occurring with any meaningful frequency, as would be expected
in the polygenic model. Genetic background, however, is a well-
recognized biological feature in inﬂuencing phenotypic variation
(Nadeau, 2001; Dowell et al., 2010; Taylor and Ehrenreich, 2015).
In the current framework though mutator/anti-mutator variants
are introduced into the genetic background, they most likely act
in an additive fashion, as described by Fisher (1918), to inﬂuence
an individual’s general mutation rate.
Recessiveness vs. Dominance
As recently discussed by Henn et al., 2015, dominance is perhaps
the most important quantity that has not been estimated from
genome-wide data characterizing the proportion of deleterious
mutations within genomes, though it’s fair to stipulate that
the proportion of deleterious mutations that are recessive
or dominant remains an open question. However, we know
particularly from examples of classic Mendelian disease but even
some cases of sporadic genetic disease, that a recessivemode is the
most commonly observed route to disease manifestation. Thus
for a particular locus, examples where half the amount of ‘wild-
type’ genetic product is insuﬃcient, or where a variant product
is dominant over a ‘wild-type’ product, are in fact rare. Though
this is what the polygenic disease model generally assumes, and
it assumes that this occurs with a high degree of frequency,
particularly in the rare-variant hypothesis where new genetic
variants are almost exclusively found in heterozygous form. The
two-hit model presented in the current framework instead posits
a generally recessive mode of inheritance where both copies of a
gene need to be inactivated.
Contributions from the Environment
Multifactorial disease are always thought of as having an
environmental component that also signiﬁcantly contributes to
disease risk. Sometimes it is much more obvious what the
environmental components may be; they include diet, exercise,
and smoking habits for conditions such as hypertension, diabetes,
obesity, and cancer for example. In other cases the factors are
much more diﬃcult to ascertain, and this is particularly the
case for multifactorial congenital disorders. It has been shown
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for example that the concordance rates for monozygotic twins
in clubfoot, cleft lip, and pyloric stenosis is fairly modest,
ranging from 17 to 46% (Christensen and Fogh-Anderson,
1993; Engell et al., 2006; Krogh et al., 2010). Pyloric stenosis
is not truly congenital, in that it becomes apparent in the ﬁrst
2–8 weeks of life; and based on previous suggestions, Krogh et al.
(2010) attribute the 54% discordance amongstmonozygotic twins
from their large-scale study to factors such as feeding practice,
maternal smoking, infant sleeping position, and postnatal use
of macrolides, as possible contributing environmental factors.
For clubfoot and cleft lip and palate, environmental factors that
have been suggested are maternal smoking and alcohol intake.
Although some of these environmental factors are sometimes
responsible for the incidence of sporadic birth defects, their
contributions to the aforementioned multifactorial diseases,
and others, may have been overestimated. Instead, discordance
betweenmonozygotic twins may be muchmore readily explained
by the current two-hit framework, where the second post-zygotic
hit is required for disease manifestation.
TESTING THE MODEL AND
DEMONSTRATING
GENOTYPE–PHENOTYPE CAUSALITY
Currently, much focus in identifying associative genetic factors
in complex genetic disease is on RVAS studies, and it has been
suggested that such population-based studies need to be of a
substantially large sample size in order to be able to detect the
causal rare variants (Lee et al., 2014; Robinson et al., 2014;
Sham and Purcell, 2014). The appropriateness of this line of
investigation can be questioned (Wagenmakers et al., 2014). It
has also been suggested that smaller family-based studies would
be ineﬀective in disease-gene identiﬁcation (Robinson et al.,
2014), though this observation is based on a framework where
an underlying polygenic architecture exists. Although in the
framework proposed here, the disease-causing alleles are likely
to be rare variants, family-based studies rather than large-scale
population based studies would be better suited for disease-
gene identiﬁcation. The framework posits a single causative gene,
however, segregation-analysis would not be entirely appropriate,
as unaﬀected siblings may also harbor the inherited mutation.
Instead blood/cheek swabs from parents and aﬀected individuals
should be obtained for sequencing, but also critical here is the
identiﬁcation of the second hit in aﬀected tissues from the
aﬀected individuals; indeed testing of unaﬀected vs. aﬀected
tissues was previously used to identify causative mutations in
sporadic forms of Proteus syndrome (Lindhurst et al., 2011). It
may not always be possible to obtain aﬀected tissue from living
patients, but wherever it is feasible to obtain such material in
a stress-free manner, they should be biopsied and sequenced.
In some situations identifying the precise regions of tissues
that are aﬀected may be less-obvious, in which case tissue of
the appropriate developmental lineage may instead be analyzed.
In other cases, a mixture of normal/aﬀected tissue might be
unavoidable, however, next-generation-sequencing approaches
and recent developments in computational methods should be
able to identify and distinguish the somatic mutations (Roth
et al., 2012; Schmitt et al., 2012; Kim et al., 2013; Josephidou
et al., 2015). A key consideration is that it would need to be
determined that the second hit has occurred on the opposite
chromosome and not in the same copy of the gene that harbors
the ﬁrst hit. This may now be possible with Nanopore sequencing
methods which allows the direct DNA sequencing of ultra-long
reads, which would allow haplotypes to be readily determined.
Although not yet commercially available, Oxford Nanopore
Technologies (ONT), have made available their ﬁrst sequencing
device (the minION) as part of an early-access program for
researchers. Early reports have indeed conﬁrmed the ability of
the device to obtain sequencing reads of tens of kilobases in
length (Laver et al., 2015). Once biallelic hits in a gene from the
aﬀected tissue have been identiﬁed, only one of which would be
more likely be present in unaﬀected tissue, and they are both
predicted to signiﬁcantly disrupt gene function, they should be
considered candidate genes. However, demonstration of causality
needs to be a central consideration, and should be assessed by
biological means. Animal models may be useful in such regards,
but care must be taken to recapitulate as closely as possible the
physiological manifestation characteristics of the disease, i.e., the
second hit needs to be induced in the correct developmental
lineage and in a relevant point in time, which may not always
be readily identiﬁable. However, cheaper and quicker genome
editing methods, such as the Crispr-Cas9 system, mean that
such investigation can be more routinely performed, and such
biological tools would also further be useful in deﬁning and
characterizing routes to therapy.
Depending on the degree of locus heterogeneity, several
disease genes may exist for a particular disease, one of which will
be disrupted in each family. Each of these genes will ﬁrst need
to be identiﬁed as described above, but thereafter, blood/cheek
swab mutation screening of these candidate genes could be
performed in all families for future diagnostics applications.
Research costs are often a limiting factor in medical genetics,
but it is important that all of the causative disease genes for
a particular disease are comprehensively identiﬁed, if at least
to provide a more satisfactory level of genetic counseling than
is currently available for all families aﬀected. In this regard,
yet another very alluring feature of ONT devices is their low
cost, since although the sequencing cost per genome is rapidly
improving for the currently commercially available technologies
(van Dijk et al., 2014; Watson, 2014), these generally operate via a
limited number of core sequencing facilities. However, the ONT
devices themselves will be much more routinely aﬀordable and
we may thus envisage smaller family-based studies which all or
most medical genetics laboratories around the world are able
to perform; this should speed up comprehensive disease gene-
identiﬁcation, providing much better deﬁned routes to therapy
in a family-tailored manner. Roughly 85% of disease causing
mutations identiﬁed in classic Mendelian disease occurs in the
protein-coding portions of the genome, and it is probably likely
we would see a similar percentage under the current framework.
Therefore, where cost is an especially limiting factor, studies
might focus on whole-exome-sequencing approaches, until
whole-genome-sequencing becomes more routinely aﬀordable.
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Finally, since an advantage of this framework is that it explains
diseases that have a more dichotomous manifestation better than
the polygenic model does, these particular diseases may be more
suitable for initial investigations.
CONCLUDING REMARKS
The primary, perhaps only reason we should harbor hopes
that such a framework is correct, is that it would make it
considerably easier to deﬁne and develop routes to therapy, as
this could be speciﬁcally targeted against the single causative
monogenic factor within families. Such hopes of course have little
or nothing to do with scientiﬁc reality and it is very possible
that the framework presented here is incorrect. The jury is still
very much out for the polygenic rare-variant hypothesis, and
the previous overwhelming consensus regarding the polygenic
common-variant hypothesis was, for most intents and purposes,
wrong. I thus feel rather apprehensive to conclude with a
comment regarding how likely it is for this proposed framework
to hold true to fact. However, the framework appears broadly
consistent with recorded observations past and present, and if
correct, the potential beneﬁts are huge; testing of the model is
clearly incumbent.
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